|Publication number||US3627583 A|
|Publication date||Dec 14, 1971|
|Filing date||Apr 29, 1969|
|Priority date||Apr 29, 1969|
|Also published as||CA937167A, CA937167A1, DE2020982A1, DE2020982B2, DE2020982C3|
|Publication number||US 3627583 A, US 3627583A, US-A-3627583, US3627583 A, US3627583A|
|Inventors||John P Troy, Anthony Monti, Frank J Lynch, Charles B Broeg|
|Original Assignee||Sucrest Corp|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (2), Non-Patent Citations (1), Referenced by (98), Classifications (40)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent  Inventors John P. Troy Hicksville; Anthony Monti, lrvington; Frank J. Lynch, Staten Island, all of N.Y.; Charles B. Broeg,
Short Hills, N .J.
] Appl. No. 820,285
 Filed Apr. 29, 1969  Patented Dec. 14, 1971  Assignee SuCrest Corporation New York, N.Y.
 DIRECT COMPRESSION VEHICLES 10 Claims, No Drawings  US. Cl 127/29, 8/79, 99/26, 99/134 R, 99/141 A, 127/63,
Primary Examiner-Joseph Scovronek Assixlan! Examiner-Sidney Marantz All0rneyKenyon & Kenyon Reilly Carr 81. Chapin ABSTRACT: Tablets are formed directly without granulation or slugging from a mixture of an active material, such as a therapeutic material, and as a direct compression vehicle, a dry, free-flowing, granular sugar composition comprising generally spherical, porous, firm agglomerates of 100 parts of solid sugar in from about 0.1 to about 30 parts of a cementum or matrix. The sugar agglomerates are obtained by:
l. Spraying a particulate solid sugar with an aqueous solution of binder;
2. Providing the resulting mixture with sufficient high intensity agitation to uniformly intermingle the sugar and binder and to build up agglomerates ofa desired size;
3. Snowballing" the agglomerates to impart a general spherical shape thereto and to firm or densify the agglomerate;
4. Drying; and if necessary,
5. Separating overand undersized agglomerates. The mix ture may also contain additives such as colors, flavorants and the like.
DIRECT COMPRESSION VEHICLES This invention relates to tablets comprising an active material and a direct compression vehicle. More particularly, this invention is concerned with tablets comprising an active material and a direct compression vehicle, which are formed from a mixture thereof without prior granulation or slugging.
There are two general methods for forming tablets, i.e., compression of a dry particulate material and trituration, or molding of a moist material, of which the first technique is by far the most frequently employed. The compression technique may be further subdivided into three major categories, viz direct compression, wet granulation and dry granulation. The direct compression technique is the most desirable, in that it employs the fewest steps and, in the case of the production of tablets containing sensitive or unstable actives, such as certain pharmaceuticals, minimizes the exposure to water or other conditions tending to adversely affect stability of the active. Unfortunately, however, it has been found that the direct compression technique is of limited applicability.
First, most active materials possess poor compression properties, and thus are unsuitable for this technique. In addition, many actives are required in such small amounts per unit dosage form that direct compression of the active alone is impractical, if not impossible. As a result, the active must be admixed with a direct compression vehicle, i.e., an inert composition which is compatible with the active and has good compressibility and binding action. In addition, the direct compression vehicle should have good flowability, good stability under normal ambient conditions, no adverse effect on tablet disintegration time, the ability to produce good tablet surfaces, and low cost.
To date, however, no material has been found which satisfies all of these criteria. For example, of the most popular of such compression vehicles, spray-dried lactose possesses poor stability and discolors on storing, dicalcium phosphate provides tablets having poor strength, and microcrystalline cellulose is expensive.
One of the principal objects of this invention is to provide a direct compression vehicle.
Another object of the invention is to provide an improved tablet as the final product as a result of the more effective quality control made possible by eliminating variables in the manufacturing process.
Another object of the invention is to permit the use of a wide variety of materials in the manufacture of tablets.
Another object of the invention is to provide a novel method of manufacturing tablets in which the complicated steps inherent in a granulation process are avoided.
Other objects and advantages in this invention will be apparent to those skilled in the art of tablet manufacture when reviewing the specification and claims of this invention.
It has been discovered in accordance with this invention that certain sugar agglomerates are well suited for use as a direct compression vehicle for the production of tablets. This material comprises generally spherical, firm, porous agglomerates of sugar particles in a cementum or matrix. The agglomerates are dry (from about 0.1 to about 3 percent moisture), free-flowing particles having particle size within the range of from about 325 to about 12 mesh. Tablets formed using such sugar agglomerates as the direct compression vehicle are uniform, possess good physical properties, do not discolor on aging, and readily dissolve in aqueous media.
These sugar agglomerates are obtained by:
l. Spraying a particulate solid sugar with an aqueous solution of binder;
2. Providing the resulting mixture with sufficient high intensity agitation to uniformly intermingle the sugar and binder and to build up agglomerates of a desired size;
3. Snowballing the agglomerates to impart a general spherical shape thereto and to firm or densify the agglomerate;
4. Drying; and if necessary,
5. Separating overand undersized agglomerates.
The particulate sugar can be a mono-, dior tri-saccharide, such as arabinose, xylose, ribose, fructose, mannose, galactose, glucose, sucrose, maltose, lactose and the like, including mixtures of two or more of such sugars, with sucrose being preferred. The particulate sugar can be obtained synthetically, or it can be a refined natural product, such as corn syrup solids, molasses solids, honey solids, maple syrup solids and the like. The particle size of the sugar is not narrowly critical so long as it is small enough to permit formation of agglomerates of the desired size. For most purposes, ordinary 6X powered sugar, of which most to 97 percent) passes through a ZOO-mesh screen, is suitable. if the agglomerate is to be employed in the production of a chewable tablet, however, it is desirable that more finely divided sugar be used to avoid grittiness."For this use, the sugar should have substantially no particles, i.e., not more than 1 percent, having sizes greater than about 40 microns, and at least 50 percent of the particles should have sizes below about 25 microns. Preferred are sugars having an average particle size of about 15 microns.
The second component which is employed to form the agglomerate is a noncrystallizing aqueous solution of a polyhydroxy compound as a binder. Illustrative polyhydroxy compounds include propylene glycol, glycerol, erythritol, arabitol, xylitol, adonitol, mannitol, dulcitol, sorbitol, sugars, such as arabinose, xylose, ribose, glucose, mannose, fructose, sucrose, maltose and lactose, dextrin and the like, with polyols of the formula HOCH (CHOH),CH OH, wherein x is l to 4, and sugars being preferred. Propylene glycol, glycerol, mannitol, sorbitol, glucose, fructose and invert sugar are of particular interest, with invert sugar being most preferred. The aqueous binder composition can be a solution of a pure compound, or can comprise two or most polyhydroxy binders. The aqueous medium can be obtained synthetically, or it can be a refined natural product, such as corn syrup, molasses, honey, maple syrup and the like. lnvert syrup is preferred.
The concentration of binder in the aqueous medium is not narrowly critical provided that it is not so high as to cause crystallization or provide solutions so viscous as to prevent spraying and intimate intermingling and uniform distribution of binder and solids. Thus, the concentration will depend upon the solubility of the binder. For example, glucose ordinarily cannot be employed in amounts greater than about 48 percent, whereas propylene glycol, glycerol, mannitol and sorbitol can be present in amounts up to about 80 percent. When invert sugar is the binder, concentrations of from about 50 to about 80 percent are employed, with concentrations of from about 70 to about 75 percent being preferred. Other than this, the amount of water in the aqueous medium should be so correlated with the desired ratio of binder to sugar that agglomeration occurs. Thus the amount of water should be insufficient to form a paste and yet sufficient to minimize the presence of powder, or unagglomerated sugar. In general, it has been found that the mixture of particulate sugar and aqueous binder medium should contain from about 2 to about 6 percent water, with amounts of about 4 percent water being preferred.
The initial contact of the solids and liquids is effected by spraying the aqueous medium onto the dry solids at a rate such that there is employed from about 0.1 to about 30 parts of binding agent per 100 parts of solid.
The mixing is ordinarily conducted at about room temperature (6575 F.). Higher and lower temperatures can be employed, if desired, provided the properties of the aqueous medium and the agglomerate product are not adversely affected. In particular, the temperature of the aqueous medium may be varied to achieve a desired viscosity for spraying. However, if the temperature is too low, e.g., below about 50 F., the aqueous medium is ordinarily too viscous to be easily sprayed; and if the temperature is too high, e.g., above about 200 F., water may evaporate too rapidly to permit adequate control of the characteristics of the binding solution. In addition, the use of elevated temperatures during processing tends to result in a discolored product, and also may cause dissolution of the dry ingredient and thus adversely affect particle size and quality.
Simultaneously with the spraying, the mixture is agitated to thoroughly intermingle the solid sugar and the aqueous binder medium and to effect agglomeration. This requires high intensity mixing, such as is obtained with a Patterson-Kelley blender or a Lodige mixer.
Agitation is continued until agglomerates of the desired size are formed, and ordinarily for a time sufficient to form agglomerates about about 325 mesh, but insufficient to form significant amounts of agglomerates larger than about l2 mesh. The size of the agglomerate is also affected by the ratio of aqueous binder to particulate sugar, with larger agglomerates being formed when a greater proportion of liquid medium is present.
The agglomerates typically have a narrow size distribution. That is, high yields, normally 80 percent or more, of the agglomerates fall within a few screen sizes. For example, when operating to produce a 20- to 80-mesh agglomerate, at least 80 percent, and in some instances 90 percent or more, of the agglomerated product will fall within this range.
Simultaneously with and/or subsequent to agglomeration, the agglomerates are snowballed, i.e., subjected to a tumbling or rolling operation, to impart a general spherical shape thereto. In addition, the agglomerates are firmed or densified whereby the bulk density is increased by about 50-100 percent over that of the dry particulate sugar, and normally is in the range of from about 30 to about 50 pounds per cubic foot.
The apparatus employed can be any suitable equipment which will achieve the desired results. A particularly preferred apparatus is the Patterson-Kelley blender, which performs all three operations of mixing, agglomerating and snowballing.
Finally, and when necessary, the agglomerates are dried to a moisture content of less than about 3 percent, and preferably less than about 1.5 percent. Although complete drying is theoretically possible, the moisture content of the product need not be less than about 0.! to 0.2 percent. The temperature at which drying occurs is not narrowly critical in all cases, but ordinarily the temperature of the agglomerate should not exceed about 140 F. To achieve such drying, the product is preferably contacted with hot air at a temperature not exceeding 190 F. A preferred drying technique is the use of a fluid bed dryer. In this manner, very fine particles, i.e., dust, are separated from the product.
If desired, the dried product may be screened. to remove oversized and undersized particles. Oversized particles are discarded or can be reduced to smaller size. Undersized particles can be recycled.
The resulting agglomerate is admixed with the active material and the resulting mixture compressed without granulation or slugging to form a tablet. The amount of the agglomerate obviously will depend upon the properties of the active and any other additives which are to be incorporatedinto the finished tablet, for it is well known that the compactibility of tablet compounds and mixtures are subject to wide variation. in general, however, the agglomerate will comprise at least percent of the tabletting mixture and, therefore, at least 10 percent of the tablet. in most cases, however, the agglomerate will comprise from about 70 to about 95 percent of the tabletting mixture and the tablet.
By the term active material is meant any material intended for ingestion and having a beneficial or desirable effect on the user. Suitable active materials include therapeutic materials, such as anesthetics, antibiotics, antitussives, vitamins, aspirin, antacids, and the like; food stufis such as cocoa, dried oats, fruit flakes, and the like; edible dyes and other food additives; and so on.
In addition to the sugar direct compression vehicle and the active material, there may be employed other commonly employed tablet and wafer additives such as coloring agents, flavorants, lubricants, gums and the like. Although ordinarily not required because of the ready solubility of the product tablet in aqueous media, disintegrants may also be employed.
The vehicle is a free-flowing granular material and imparts improved flow characteristics to the active material and other components of the blend, thereby assuring ease of tabletting. The blend of direct compression vehicle, active material and other additives is mixed and directly compressed to form a tablet employing conventional techniques and apparatus.
The following examples are illustrative. As used throughout this application, all parts and percentages are by weight unless otherwise stated.
EXAMPLE I To parts of finely pulverized sucrose is rapidly added over a period of 5 minutes by spraying at room temperature and while agitating the pulverized sugar l4 parts of an aqueous invert sugar solution (72 percent total solids) in a PattersonKelley liquids-solids blender. After continuing agitation for an additional 10 minutes, the agglomerated material is screened through a vibrating l6-mesh screen and the screened material is dried to a moisture content of 1.5 percent or less. To 97 parts of dry agglomerated product is added, under agitation, 1 part of dry citric acid, 0.25 part of dry flavoring material and 1.75 part of magnesium stearate. The properly blended material is fed to a tabletting press and wafers are formed from it.
EXAMPLE 2 Employing procedures similar to those described in example 1, 98 parts of finely pulverized sucrose is mixed with about 6.7 parts of an aqueous invert sugar solution (30 percent total solids). The agglomerated material is screened through a vibrating mesh screen and the screened material is dried to a moisture content of 1.5 percent or less.
Equal parts of the agglomerate and vitamin C are blended. This blend can be further mixed with other dry ingredients such as minerals or other nutritionally active ingredients before being compressed into tablets.
EXAMPLE 3 Employing procedures similar to those described in example l, a blend of lOO parts of finely pulverized dextrose monohydrate is sprayed with 14 parts of dextrose syrup (48 percent total solids). The agglomerated material is screened and dried to a moisture content of 1.5 percent or less.
The agglomerated material can be directly compacted after adding and blending the proper release agent (magnesium stearate). Rapidly disintegrating ingredients can also be included in the formulation prior to tabletting.
EXAMPLE 4 Employing procedures similar to those described in example l, a blend of 90 parts of finely pulverized sucrose and 10 parts of finely comminuted dextrose are sprayed with about 14 parts of invert syrup (72 percent total solids). The agglomerated materials is screened, and dried to a moisture content of 1.5 percent or less.
Equal parts of the agglomcrate and aluminum hydroxide are blended together. This blend can be further mixed with small amounts of flavoring or other dry ingredients before being compressed into a commercial antacid tablet.
EXAMPLE 5 Employing procedures similar to those described in example l, parts of finely pulverized dried molasses are sprayed with about 6.5 parts of afi'mation syrup (76 percent total solids). The agglomerated material is screened and dried to a moisture content of 1.5 percent or less.
Equal parts of the agglomerate and dried ground oats are blended. This product can be further mixed with other dry ingredients such as minerals or other nutritives. After compacting, wafers for animal feeding are obtained.
EXAMPLE 6 To 90 parts of pulverized sucrose having an average particle size of microns, less than 1 percent thereof exceeding 40 microns, and more than 50 percent thereof less than 25 microns in size, the said pulverized sugar being in a Patterson- Kelley liquids-solids blender, there is rapidly added by spraying at room temperature (65 F.), and while agitating the pulverized sucrose, about 14 parts of an aqueous invert sugar solution (72 Brix). A small amount of monocalcium phosphate is added to adjust the pH to 4.5-4.8 to prevent discoloration. After the addition of the invert syrup has been completed, the blender is run for about 2 minutes to complete the agglomeration. The total time of operation, i.e., spraying and agglomeration, is about 6 minutes.
The resultant agglomerated material, which contains about 3.8 percent water, is then screened through a vibrating mesh screen. The agglomerates coarser than 20 mesh are still relatively soft and can be rubbed through an auxiliary screen and added to the first product. The screened material is then placed in a rotary drier and warm air at about 180 F. is circulated through the drier to dry the agglomerates to a water content of 1 percent. The drier is operated so that the temperature of the agglomerates does not rise about 140 F. The dried product is then further screened on an 80-mesh screen. The material remaining on the screen is the finished product. That passing through the screen may be returned to the blender for reprocessing, or may be employed as a fine particle size granular product.
This agglomerate can be blended in accordance with the following recipes and compressed.
A. CONFECTIONERY TABLETS OR WAFERS 1. Lemon Flavored Confectionery Tablet: 100.0 pts. agglomerate 1.0 pt. citric acid, dry
0.25 pt. encapsulated lemon flavor 0.10 pt. yellow color No. 5
1.0 pt. magnesium stearate 2. Grape Flavored Tablet:
50.0 pts. agglomerate 50.0 pts. 6X powdered sugar 2.0 pts. tartaric acid 0.25 pt. grape flavor 0.05 pt. grape color 0.5 pt. calcium stearate 3. Cherry Flavored Confectionery Tablet: 100.0 pts. agglomerate 2.0 pts. fumaric acid 0.2 pts. cherry flavor 0.1 pt. red color 1.0 pt. magnesium stearate B. PHARMACEUTICAL FORMULATIONS 50.0 pts. agglomerate 37.5 pts. aluminum hydroxide 1.0 pt. magnesium stearate 100.0 pts. 25.0 pts. 5.0 pts.
1 drop 2.0 pts.
agglomerate acetyl salicylic acid corn starch magnesium stearate Other active ingredients of use in blends with the agglomerate are: sodium bicarbonate, acetanilid, phenacetin, and magnesium trisilicate. C. SPECIALTY PRODUCTS 1. Invertase Sugar Tablet 96.4 pts. agglomerate 3.6 pts. liquid triple strength invertase (K=0.9) 1.0 pt. magnesium stearate 2. Cocoa-Sugar Tablet 90.0 pts. agglomerate 10.0 pts. high fat cocoa 0.2 pts. dendritic salt 1.0 pt. magnesium stearate After blending, the mixture is tabletted to form a cocoasugar tablet.
3. Sugar-Synthetic Sweetener Tablet 450.0 pts. agglomerate 7.16 pts. calcium cyclamate 0.8 pts. sodium saccharin 5.0 pts. calcium stearate 4. Highly Concentrated Color Tablet 90.0 pts. agglomerate 10.0 pts. dried yellow FD&C No. 6
10.0 pts. sodium benzoate 5. Yeast Food Tablet 34.0 pts. calcium sulfate (ZH O) 23.0 pts. flour 9.0 pts. ammonium chloride 0.25 pt. potassium bromate 17.75 pts. sodium dihydrogen phosphate 16.0 pts. salt 900.0 pts. agglomerate 10.0 pts. magnesium stearate In the foregoing examples, the direct compression vehicle has been a spherical agglomerate. In some instances, in which a high degree of composition uniformity is desired, the use of the agglomerate per se has been found disadvantageous. It is readily appreciated that the ratio of invert to particulate sugar increases with increasing agglomerate size. For example, in the case of a product having agglomerates in the -100 mesh range, the invert content of the ZOO-mesh size particles is substantially less than the invert content of the 80-mesh particles.
It has been further found that the agglomerates tend to segregate according to size upon handling. For example, when a 80-200 mesh fraction of the agglomerates is stored in a bag, the ZOO-mesh particles tend to settle out in the bottom of the bag during handling. As a result of the different composition and size segregation, the composition of tablets made from the agglomerates will vary depending upon whether the agglomerate is taken from the top or the bottom of the bag.
To avoid such product variations, it has been found desirable to pulverize the agglomerate and then compact the pulverized agglomerate, as for example by the use of a Fitzpatrick Chilsonator, and reduce the resulting compacted sheet to particles of a desired size. If desired, the granules of compacted agglomerate may be screened to provide a product of more restricted size variation.
The resulting compacted agglomerate may be employed in a manner identical to the agglomerate itself. Thus, it may be substituted for the agglomerate in any of the foregoing examples to achieve a tablet of substantially identical characteristics.
What is claimed is:
1. A method for preparing tablets containing as a direct compression vehicle a sugar composition comprising the steps of (a) forming a unifonn nongranulated mixture of an active material and a dry, free-flowing, generally spherical, porous agglomerate of parts of a solid pulverized sugar in 0.1 to about 30 parts of a matrix of a polyhydroxy compound, and (b) compressing said mixture into tablets, said agglomerate comprising at least 10 percent of said mixture, and having a particle size of from about 12 to about 325 mesh, a moisture content of from about 0.1 to about 3 percent, and having been prepared by a process including the steps of: (l) Spraying a particulate solid sugar with an aqueous solution of binder; (2) Providing the resulting mixture with sufficient high intensity agitation to uniformly intermingle the sugar and binder and to build up agglomerates of a desired size; and (3) Snowballing the agglomerates to impart a general spherical shape thereto and to firm or densify the agglomerate.
2. A tablet prepared in accordance with claim 1.
3 A method according to claim I, wherein said matrix is a carbohydrate.
4. A tablet prepared in accordance with claim 3.
5. A method according to claim 3, wherein said sugar is sucrose and said carbohydrate is invert sugar.
6. A tablet prepared in accordance with claim 5.
7. A method for preparing a direct compression vehicle comprising compacting a dry, free-flowing, generally spherical, porous agglomerate of I parts of a solid pulverized sugar in 0.] to 30 parts of a matrix of a polyhydroxy compound, said agglomerate having a particle size of from about 12 to about 325 mesh and a moisture content of from about 0.1 to about 3 percent, said agglomerate being prepared by a process including the steps of:
l. Spraying a particulate solid sugar with an aqueous solution of binder;
2. Providing the resulting mixture with sufficient high intensity agitation to uniformly intermingle the sugar and binder and to build up agglomerates of a desired size; and
3. Snowballing the agglomerates to impart a general spherical shape thereto and to firm or densify the agglomerate,
and thereafter comminuting said compacted agglomerate to a desired particle size.
8. The product of claim 7.
9. A method for preparing a tablet comprising forming a uniform admixture of the product of claim 8 and active material, said product comprising at least 10 percent of said mixture, and compressing the mixture into tablets.
10. A tablet produced according to claim 9.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3169888 *||Mar 5, 1962||Feb 16, 1965||American Sugar||Pressed crystal sugar tablet and method of manufacturing same|
|US3305447 *||Jun 12, 1963||Feb 21, 1967||American Sugar||Tabletting sugar and method of preparing same|
|1||*||G. Milosovich, Drug and Cosmetic Industry, 92(5), 557 558, 656, 662 669 (1963).|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US3873694 *||Sep 27, 1973||Mar 25, 1975||Cpc International Inc||Direct compression tabletting composition and pharmaceutical tablets produced therefrom|
|US3900569 *||Sep 15, 1972||Aug 19, 1975||Sucrest Corp||Direct compression vehicle|
|US4073931 *||Mar 25, 1975||Feb 14, 1978||Teijin Limited||Nitroglycerine inclusion compounds with cyclodextrin and composition containing same|
|US4119738 *||May 17, 1976||Oct 10, 1978||Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler||Sweet material|
|US4312889 *||Apr 30, 1980||Jan 26, 1982||Design & Funding, Inc.||Liquid carrier concentrate for pre-loaded cup|
|US4349542 *||May 5, 1980||Sep 14, 1982||National Research Development Corporation||Mixture containing active ingredient and dendritic crystalline sugar for tableting|
|US4375468 *||Apr 8, 1982||Mar 1, 1983||Verex Laboratories, Inc.||Constant order release aspirin composition and method of treating arthritis|
|US4384005 *||Jun 2, 1981||May 17, 1983||General Foods Corporation||Non-friable, readily-soluble, compressed tablets and process for preparing same|
|US4495177 *||Jan 17, 1983||Jan 22, 1985||Shaklee Corporation||Gel tableting agent|
|US4508740 *||Jul 11, 1983||Apr 2, 1985||General Foods Corporation||Tabletted beverage composition containing dipeptide sweetener and process therefore|
|US4572916 *||Nov 21, 1983||Feb 25, 1986||Tate & Lyle Public Limited Co.||Tablets|
|US4684534 *||Feb 19, 1985||Aug 4, 1987||Dynagram Corporation Of America||Quick-liquifying, chewable tablet|
|US4692340 *||Oct 4, 1985||Sep 8, 1987||Institut fur Getreideverarbeitung im VEB Kombinat Nahrungsmittel und Kaffee||Procedure for the production of a granulated infant milk food product|
|US4994276 *||Sep 19, 1988||Feb 19, 1991||Edward Mendell Co., Inc.||Directly compressible sustained release excipient|
|US5128143 *||Mar 9, 1990||Jul 7, 1992||Edward Mendell Co., Inc.||Sustained release excipient and tablet formulation|
|US5135757 *||Jan 16, 1991||Aug 4, 1992||Edward Mendell Co., Inc.||Compressible sustained release solid dosage forms|
|US5169639 *||Jul 25, 1991||Dec 8, 1992||Edward Mendell Co., Inc.||Controlled release verapamil tablets|
|US5254355 *||May 29, 1992||Oct 19, 1993||Kraft General Foods, Inc.||Process for beverage tablets and products therefrom|
|US5472711 *||Jul 30, 1992||Dec 5, 1995||Edward Mendell Co., Inc.||Agglomerated hydrophilic complexes with multi-phasic release characteristics|
|US5478574 *||Jul 20, 1993||Dec 26, 1995||Edward Mendell Co., Inc.||Agglomerated hydrophilic complexes with multi-phasic release characteristics|
|US5670168 *||Jun 17, 1996||Sep 23, 1997||Edward Mendell Co., Inc.||Agglomerated hydrophilic complexes with multi-phasic release characteristics|
|US5738900 *||Aug 30, 1996||Apr 14, 1998||Kraft Foods, Inc.||Process for making a readily-dispersible, dry food mix|
|US6039813 *||Jun 5, 1990||Mar 21, 2000||Xyrofin Oy||Fructose-based granulated product and a process for the production thereof|
|US6045850 *||May 8, 1998||Apr 4, 2000||M & C Sweeteners, Llc||Low-calorie compounded cocoa composition|
|US6077532 *||Sep 2, 1996||Jun 20, 2000||Euro-Celtique, S.A.||Pharmaceutical ion exchange resin composition|
|US6168811||Jun 17, 1999||Jan 2, 2001||Kellogg Company||Fortified edible compositions and process of making|
|US6177110 *||Jun 23, 1998||Jan 23, 2001||Candy Novelty Works Ltd.||Lollipop with edible stick|
|US6960356||Jul 2, 1999||Nov 1, 2005||Ranbaxy Laboratories Limited||Orally administered drug delivery system providing temporal and spatial control|
|US6982094||Sep 28, 2001||Jan 3, 2006||Mcneil-Ppc, Inc.||Systems, methods and apparatuses for manufacturing dosage forms|
|US7297345||Jun 16, 2004||Nov 20, 2007||Mcneil-Ppc, Inc.||Systems, methods and apparatuses for manufacturing dosage forms|
|US7323192||Sep 28, 2001||Jan 29, 2008||Mcneil-Ppc, Inc.||Immediate release tablet|
|US7635490||Mar 21, 2003||Dec 22, 2009||Mcneil-Ppc, Inc.||Modified release dosage form|
|US7695528||Feb 15, 2007||Apr 13, 2010||Delavau Llc||Calcium carbonate granulation|
|US7807125||Oct 25, 2006||Oct 5, 2010||Delavau Llc||Calcium carbonate granulation|
|US7807197||Sep 28, 2002||Oct 5, 2010||Mcneil-Ppc, Inc.||Composite dosage forms having an inlaid portion|
|US7838026||Oct 28, 2003||Nov 23, 2010||Mcneil-Ppc, Inc.||Burst-release polymer composition and dosage forms comprising the same|
|US7850988||Oct 25, 2006||Dec 14, 2010||Delavau Llc||Calcium carbonate granulation|
|US7879363||Jan 11, 2008||Feb 1, 2011||Ritter Pharmaceuticals, Inc.||Method for increasing lactose tolerance in mammals exhibiting lactose intolerance|
|US7883552||Feb 15, 2007||Feb 8, 2011||Delavau Llc||Calcium carbonate granulation|
|US7968120||Sep 28, 2002||Jun 28, 2011||Mcneil-Ppc, Inc.||Modified release dosage forms|
|US7972624||Feb 24, 2009||Jul 5, 2011||Shun-Por Li||Method of manufacturing modified release dosage forms|
|US8114328||Aug 4, 2004||Feb 14, 2012||Mcneil-Ppc, Inc.||Method of coating a dosage form comprising a first medicant|
|US8440236||Oct 25, 2006||May 14, 2013||Delavau L.L.C.||Calcium carbonate granulation|
|US8486668||Aug 4, 2011||Jul 16, 2013||Ritter Pharmaceuticals, Inc.||Prebiotic formulations and methods of use|
|US8492124||Feb 17, 2010||Jul 23, 2013||Ritter Pharmaceuticals, Inc.||Prebiotic formulations and methods of use|
|US8545887||Sep 28, 2002||Oct 1, 2013||Mcneil-Ppc, Inc.||Modified release dosage forms|
|US8603544||Jan 30, 2013||Dec 10, 2013||Delavau L.L.C.||Calcium carbonate granulation|
|US8609140||Jan 31, 2013||Dec 17, 2013||Delavau L.L.C.||Calcium carbonate granulation|
|US8617619||Jan 30, 2013||Dec 31, 2013||Delavau L.L.C.||Calcium carbonate granulation|
|US8663706||Jan 30, 2013||Mar 4, 2014||Delavau L.L.C.||Calcium carbonate granulation|
|US8668936||Apr 20, 2012||Mar 11, 2014||Delavau L.L.C.||Calcium carbonate granulation|
|US8673190||Dec 7, 2011||Mar 18, 2014||Mcneil-Ppc, Inc.||Method for manufacturing dosage forms|
|US8673352||Apr 15, 2005||Mar 18, 2014||Mcneil-Ppc, Inc.||Modified release dosage form|
|US8697142||Aug 9, 2012||Apr 15, 2014||Delavau L.L.C.||Calcium carbonate granulation|
|US8709499||Apr 20, 2012||Apr 29, 2014||Delavau L.L.C.||Calcium carbonate granulation|
|US8728173||Aug 10, 2012||May 20, 2014||Delavau L.L.C.||Calcium carbonate granulation|
|US8728538||Apr 20, 2012||May 20, 2014||Delavau L.L.C.||Calcium carbonate granulation|
|US8741355||Apr 20, 2012||Jun 3, 2014||Delavau L.L.C.||Calcium carbonate granulation|
|US8784902||Apr 20, 2012||Jul 22, 2014||Delavau L.L.C.||Calcium carbonate granulation|
|US8785160||Apr 28, 2011||Jul 22, 2014||Ritter Pharmaceuticals, Inc.||Prebiotic formulations and methods of use|
|US8790713||Apr 20, 2012||Jul 29, 2014||Delavau, L.L.C.||Calcium carbonate granulation|
|US8815302||Apr 20, 2012||Aug 26, 2014||Delavau Llc||Calcium carbonate granulation|
|US8821946||Apr 20, 2012||Sep 2, 2014||Delavau L.L.C.||Calcium carbonate granulation|
|US8883223||Jan 15, 2014||Nov 11, 2014||Delavau Llc||Calcium carbonate granulation|
|US8900642||Apr 16, 2012||Dec 2, 2014||Delavau Llc||Calcium carbonate granulation|
|US8968795||Apr 20, 2012||Mar 3, 2015||Delavau Llc||Calcium carbonate granulation|
|US8993002||Sep 19, 2014||Mar 31, 2015||Delavau Llc||Calcium carbonate granulation|
|US9138414||Sep 14, 2007||Sep 22, 2015||Delavau Llc||Calcium supplement having enhanced absorption|
|US9226933||Mar 26, 2008||Jan 5, 2016||Ritter Pharmaceuticals, Inc.||Methods and compositions for treating lactose intolerance|
|US9333176||Feb 23, 2015||May 10, 2016||Delavau L.L.C.||Calcium carbonate granulation|
|US9511027||Apr 20, 2012||Dec 6, 2016||Delavau L.L.C.||Calcium supplement having enhanced absorption|
|US9579340||Sep 4, 2015||Feb 28, 2017||Ritter Pharmaceuticals, Inc.||Prebiotic formulations and methods of use|
|US9592248||Sep 21, 2015||Mar 14, 2017||Ritter Pharmaceuticals, Inc.||Prebiotic formulations and methods of use|
|US20030012820 *||Jun 12, 2001||Jan 16, 2003||Upadhyay Ajay Hasmukhlal||Compressible guaifenesin compositions, method for making same and method for making compressed guaifenesin dosage forms therefrom|
|US20030068373 *||Sep 28, 2001||Apr 10, 2003||Joseph Luber||Immediate release tablet|
|US20040170750 *||Sep 28, 2002||Sep 2, 2004||Bunick Frank J.||Edible composition and dosage form comprising an edible shell|
|US20040234660 *||May 13, 2004||Nov 25, 2004||Bauman Michael N.||Process for compression molding a dried aerated confection|
|US20040256760 *||Jun 16, 2004||Dec 23, 2004||Sowden Harry S.||Systems, methods and apparatuses for manufacturing dosage forms|
|US20050019376 *||Sep 28, 2002||Jan 27, 2005||Mcnally Gerard P.||Dosage form containing a confectionery composition|
|US20050191404 *||Nov 19, 2003||Sep 1, 2005||Detora Sigismondo A.||Process for manufacture of granular sugar ingredient for compressed confections having improved strength|
|US20060013807 *||Jul 13, 2004||Jan 19, 2006||Chapello William J||Rapidly disintegrating enzyme-containing solid oral dosage compositions|
|US20070045890 *||Oct 25, 2006||Mar 1, 2007||Delavau Llc||Calcium carbonate granulation|
|US20070196439 *||Feb 1, 2007||Aug 23, 2007||Catani Steven J||Lactose-reduced dairy compositions and related methods|
|US20080112941 *||Jan 11, 2008||May 15, 2008||Ritter Andrew J||Method for increasing lactose tolerance in mammals exhibiting lactose intolerance|
|US20080126195 *||Jul 22, 2005||May 29, 2008||Ritter Andrew J||Methods and Compositions for Treating Lactose Intolerance|
|US20100015320 *||Jul 16, 2009||Jan 21, 2010||Steviva Brands, Inc.||Natural sugar replacement and process for preparing the same|
|US20110086093 *||Dec 20, 2010||Apr 14, 2011||Ritter Pharmaceuticals, Inc.||Method for increasing lactose tolerance in mammals exhibiting lactose intolerance|
|US20110189148 *||Jun 25, 2009||Aug 4, 2011||Ritter Pharmaceuticals, Inc.||Lactose compositions with decreased lactose content|
|EP0745382A1 *||Jan 27, 1995||Dec 4, 1996||Yamanouchi Pharmaceutical Co. Ltd.||Intraorally soluble compressed molding and process for producing the same|
|EP0745382A4 *||Jan 27, 1995||Oct 29, 1997||Yamanouchi Pharma Co Ltd||Intraorally soluble compressed molding and process for producing the same|
|EP2395972A1 *||Feb 5, 2010||Dec 21, 2011||Liangping Yu||Particulate composition and the method of making the same|
|EP2395972A4 *||Feb 5, 2010||Feb 12, 2014||Liangping Yu||Particulate composition and the method of making the same|
|WO1990014821A1 *||Jun 5, 1990||Dec 13, 1990||Xyrofin Oy||A fructose-based granulated product and a process for the production thereof|
|WO1999065336A1 *||Jun 17, 1999||Dec 23, 1999||Kellogg Company||An edible composition containing agglomerated fortificant particles and method of making and an edible agglomerated granule|
|WO2000057714A2 *||Feb 28, 2000||Oct 5, 2000||General Mills, Inc.||Concentrated dessert cube, methods of manufacture, and packaging therefor|
|WO2000057714A3 *||Feb 28, 2000||Apr 26, 2001||Phillip Arend||Concentrated dessert cube, methods of manufacture, and packaging therefor|
|WO2003026613A1 *||Sep 28, 2002||Apr 3, 2003||Mcneil-Ppc, Inc.||Fondant-based pharmaceutical composition|
|WO2003026616A1 *||Sep 28, 2002||Apr 3, 2003||Mcneil-Ppc, Inc.||Edible composition and dosage form comprising an edible shell|
|U.S. Classification||127/29, 424/722, 127/63, 424/686, 424/723, 424/687, 424/695, 426/539, 426/548, 426/285, 426/590, 514/772, 424/720, 426/453, 424/606, 426/650, 424/690|
|International Classification||C13B50/02, A61K9/26, A23L1/00, B01J2/22, A23G3/02, A23G3/34, A61K9/20|
|Cooperative Classification||A23L1/0026, A23G3/0294, A61K9/2018, A23G3/346, A23G2200/06, A23G2200/00, C13B50/02, B01J2/22, A23G3/0289|
|European Classification||C13B50/02, A23G3/34E, A61K9/20H4B, A23L1/00P2D, A23G3/02M8T, B01J2/22, A23G3/02M12|